- On October 6, 2021, California Governor Gavin Newsom signed AB 45 into law, which allows for the inclusion of hemp and cannabinoids (e.g., CBD), extracts, or derivatives of hemp in
Delta-8 THC Products Are a Growing Concern for FDA
Posted on
- Delta-8 tetrahydrocannabinol (Delta-8 THC), as found in many popular products, is a compound that can be made by chemical conversion of cannabidiol (CBD) extracted from hemp. Delta-8 THC is an
…
Continue Reading Delta-8 THC Products Are a Growing Concern for FDA
Hemp Industry Submits Comments on Draft CAOA
Posted on
- On August 13, the U.S. Hemp Roundtable, a hemp industry trade association, filed a formal response to the Cannabis Administration and Opportunity Act (CAOA), just over one month after the
…
Continue Reading Hemp Industry Submits Comments on Draft CAOA
FDA Reaffirms Need for More Safety Data on CBD
Posted on
- Previous New Dietary Ingredient Notifications (NDINs) for cannabidiol (CBD) products, i.e., NDINs #984, #1116, #1117, #1128, and #1135, were not filed based solely on FDA’s determination (discussed here) that
…
Continue Reading FDA Reaffirms Need for More Safety Data on CBD
CBA Calls on FDA to Regulate CBD Products
Posted on
- In letters to Acting FDA Commissioner Janet Woodcock and Senator Ron Wyden (D – OR), the Consumer Brands Association (CBA) renewed its call for government action on cannabidiol (CBD) regulation
…
Continue Reading CBA Calls on FDA to Regulate CBD Products
Senators Unveil Draft Bill with Pathway for CBD
Posted on
- Senators Chuck Schumer (D-NY), Cory Booker (D-NJ), and Ron Wyden (D-OR) unveiled a lengthy discussion draft titled the Cannabis Administration and Opportunity Act on July 14. The draft language is
…
Continue Reading Senators Unveil Draft Bill with Pathway for CBD
New Bipartisan Senate Bill Seeks Movement on CBD
Posted on
- U.S. Senators Ron Wyden (D-OR), Rand Paul (R-KY) and Jeff Merkley (D-OR) introduced S. 1698 on May 19, a bill to allow the use of cannabidiol (CBD) and other hemp
…
Continue Reading New Bipartisan Senate Bill Seeks Movement on CBD
Industry to Support Cannabis Testing Research
Posted on
- The National Institute of Standards and Technology (NIST), housed within the U.S. Department of Commerce, has partnered with industry to further its efforts for improved testing methodologies in cannabis as
…
Continue Reading Industry to Support Cannabis Testing Research
FDA Issues Warning Letters to Companies Selling CBD Products for Pain Relief
Posted on
- Last week the FDA issued warning letters to Honest Globe, Inc. (March 15, 2021) and Biolyte Laboratories, LLC (March 18, 2021) for selling products containing cannabidiol (CBD) in violation of
…
Continue Reading FDA Issues Warning Letters to Companies Selling CBD Products for Pain Relief
CBD Suit Stayed Pending Further Action from FDA or Congress
Posted on
- On March 3, 2021, the U.S. District Court for the Central District of California invoked the primary jurisdiction doctrine to stay a consumer class action asserting various causes of action
…
Continue Reading CBD Suit Stayed Pending Further Action from FDA or Congress